A number of other equities analysts have also weighed in on RHHBY. Deutsche Bank Aktiengesellschaft lowered shares of Roche from a buy rating to a hold rating in a research report on Wednesday. Stifel Nicolaus began coverage on shares of Roche in a research report on Monday, February 28th. They set a buy rating on the stock. Morgan Stanley lowered their price target on shares of Roche from CHF 395 to CHF 370 and set an equal weight rating on the stock in a research report on Thursday. JPMorgan Chase & Co. lowered their price target on shares of Roche from CHF 390 to CHF 370 and set a neutral rating on the stock in a research report on Friday, March 11th. Finally, UBS Group lowered shares of Roche from a neutral rating to a sell rating in a research report on Tuesday, April 19th. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of Hold and a consensus target price of $310.50.
Shares of OTCMKTS RHHBY opened at $39.54 on Friday. The company’s 50-day simple moving average is $48.30 and its 200-day simple moving average is $48.89. Roche has a 52-week low of $39.40 and a 52-week high of $53.86. The company has a current ratio of 0.93, a quick ratio of 0.73 and a debt-to-equity ratio of 0.57.
Institutional investors have recently added to or reduced their stakes in the company. Meeder Asset Management Inc. purchased a new stake in shares of Roche in the 1st quarter valued at approximately $33,000. First Horizon Advisors Inc. grew its holdings in shares of Roche by 76.4% in the fourth quarter. First Horizon Advisors Inc. now owns 709 shares of the company’s stock valued at $35,000 after purchasing an additional 307 shares in the last quarter. Elmwood Wealth Management Inc. acquired a new position in shares of Roche in the fourth quarter valued at approximately $128,000. Roanoke Asset Management Corp NY acquired a new position in Roche during the 4th quarter worth approximately $207,000. Finally, Enterprise Financial Services Corp acquired a new position in Roche during the 4th quarter worth approximately $255,000. 0.21% of the stock is currently owned by institutional investors and hedge funds.
About Roche (Get Rating)
Roche Holding AG engages in the prescription pharmaceuticals and diagnostics businesses in Switzerland, Germany, and internationally. The company offers pharmaceutical products for treating oncology, neuroscience, infectious, immunology, cardiovascular and metabolism, ophthalmology, and respiratory, as well as anemia, cancer, dermatology, hemophilia, inflammatory and autoimmune, neurological, and transplantation.
- Get a free copy of the StockNews.com research report on Roche (RHHBY)
- Is Electronic Arts (NASDAQ: EA) Suddenly A Safe Haven?
- Beyond Meat Stock Value is Improving
- The Travel Sector Is Getting Upgraded
- Carvana Insiders Buy Shares But Maybe You Shouldn’t
- Dutch Bros Gets Scalded By Inflation
Receive News & Ratings for Roche Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roche and related companies with MarketBeat.com's FREE daily email newsletter.